Evoke Pharma
EVOK
EVOK was delisted on the 16th of December, 2025.
10 hedge funds and large institutions have $71.8K invested in Evoke Pharma in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, reducing their positions, and 1 closing their positions.
0.04% more ownership
Funds ownership: 2.01% → 2.05% (+0.04%)
0% more funds holding
Funds holding: 10 → 10 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
22% less capital invested
Capital invested by funds: $92.4K → $71.8K (-$20.6K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$802 |
| 2 |
Morgan Stanley
New York
|
+$461 |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$253 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CWP
Concord Wealth Partners
Abingdon,
Virginia
|
-$43 |
EVOK Hedge Fund Activity: Q4 2023 in Review
10 of the 6,871 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q4 2023, worth a combined $71.8K — down 22% from $92.4K a quarter earlier.
Fund positioning in EVOK was balanced in Q4 2023: 1 fund opened new positions, 1 closed out, 2 added to existing stakes and 0 trimmed.
The largest buyer was Tower Research Capital (TRC), adding an estimated $802. The largest seller was Concord Wealth Partners, exiting entirely with an estimated $43 sold.
- 10 institutional investors held Evoke Pharma (EVOK) as of Q4 2023, unchanged from Q3 2023.
- Funds reported $71.8K of Evoke Pharma stock for Q4 2023, down 22% quarter-over-quarter.
- 1 fund opened new Evoke Pharma positions in Q4 2023 and 1 closed out, a net change of 0 holders.
- The largest Evoke Pharma buyer in Q4 2023 was Tower Research Capital (TRC), an estimated $802 added.
- The largest Evoke Pharma seller in Q4 2023 was Concord Wealth Partners, an estimated $43 sold.
Based on aggregated 13F filings for Q4 2023.